Analysts Offer Predictions for VRDN Q4 Earnings

Key Points

• Viridian beat quarterly estimates: It reported a loss of $0.81 per share versus the expected $1.02 loss, and revenue of $25.75 million compared with the $4.72 million forecast.
• Analysts remain broadly bullish: HC Wainwright forecasts a Q4 2027 loss of $0.16 per share and rates the stock “Buy” with a $40 target. The consensus rating is “Moderate Buy,” with an average price target of $41.
• Several firms raised price targets, while upcoming pipeline and launch milestones—including an anticipated elegrobart filing in Q1 2027—remain in focus; Viridian is still loss-making.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Viridian Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.07) per share.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The company had revenue of $25.75 million during the quarter, compared to analyst estimates of $4.72 million.

A number of other equities analysts also recently issued reports on the stock. Wedbush increased their price objective on shares of Viridian Therapeutics from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday. Weiss Ratings raised shares of Viridian Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, September 14th. Leerink Partners boosted their price objective on shares of Viridian Therapeutics from $50.00 to $54.00 and gave the stock an "outperform" rating in a research note on Thursday. Needham & Company LLC upped their target price on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Truist Financial increased their target price on Viridian Therapeutics from $39.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Viridian Therapeutics Trading Down 1.8%

NASDAQ VRDN opened at $28.55 on Friday. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of -7.43 and a beta of 1.07. The company's 50-day simple moving average is $21.88 and its two-hundred day simple moving average is $21.83.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC raised its stake in shares of Viridian Therapeutics by 27.6% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 90,019 shares of the company's stock valued at $1,853,000 after buying an additional 19,466 shares during the last quarter. 71 West Capital Partners boosted its stake in shares of Viridian Therapeutics by 4.1% in the third quarter. 71 West Capital Partners now owns 22,282 shares of the company's stock worth $459,000 after buying an additional 882 shares during the last quarter. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics during the third quarter worth about $97,000. Pictet Asset Management Holding SA raised its position in Viridian Therapeutics by 13.5% during the third quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company's stock valued at $262,000 after acquiring an additional 1,516 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in Viridian Therapeutics during the third quarter valued at approximately $216,000.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Q3 results beat expectations. Viridian reported a loss of $0.81 per share, narrower than analysts’ expected $1.02 loss, while revenue of $25.75 million topped the $4.72 million estimate. Shares were reported to have gapped up after the results. Q3 results and business update
• Positive Sentiment: Analysts lifted targets and reiterated bullish ratings. Leerink Partners raised its target to $54, RBC to $41, Truist to $42, and Wedbush to $42; HC Wainwright raised its target to $40 and Needham to $38. These revisions signal improved analyst expectations. Wedbush price-target update
• Positive Sentiment: Product and pipeline milestones remain in focus. Viridian is targeting broad coverage for its Lumvoa launch over the next 6–9 months and has indicated it expects to file an elegrobart biologics license application in Q1 2027. Investors are also awaiting VRDN-008 data. Lumvoa launch and elegrobart filing plans
• Neutral Sentiment: Despite the earnings beat, Viridian remains loss-making, and its quarterly loss widened compared with the year-earlier period. The beat and higher revenue may be encouraging, but sustained commercial execution and clinical progress will be important.
• Negative Sentiment: A recent commentary argued the stock may be overvalued even with its new launch, highlighting valuation as a potential headwind after the positive earnings and analyst updates. Valuation commentary

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company's lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian's pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.